Skip to content
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Ophthalmology

Understanding Your CRVO Diagnosis

At a Glance

Central Retinal Vein Occlusion (CRVO), often called an "eye stroke," is a blockage in the retina's main exit vein causing sudden vision changes. While serious, it is not life-threatening. Highly effective treatments like anti-VEGF therapy are available to reduce swelling and protect your vision.

Receiving a diagnosis of Central Retinal Vein Occlusion (CRVO) can be an overwhelming experience. Many patients feel a sudden wave of anxiety, especially when they hear the condition referred to as an “eye stroke” [1][2]. It is completely normal to feel scared or confused when your vision changes so abruptly. However, understanding what is happening inside your eye and knowing that modern medicine has powerful tools to manage this condition can help you regain a sense of control.

Understanding the “Eye Stroke”

The term “eye stroke” is used because, much like a stroke in the brain, CRVO involves a sudden blockage in a blood vessel [1]. In this case, the blockage occurs in the central retinal vein, which is the main “exit pipe” that carries blood away from the retina (the light-sensitive tissue at the back of your eye) [1][3].

To visualize this, think of your eye’s blood circulation like a plumbing system:

  • The Arteries are the “entry pipes” bringing fresh, oxygen-rich blood into the eye.
  • The Veins are the “exit pipes” carrying blood back out.
  • The Occlusion (blockage) acts like a clog in the main exit pipe.

When the blood cannot exit through the vein, it backs up. This pressure causes fluid and blood to leak into the retina, leading to swelling called macular edema [1][3]. This swelling is usually the primary reason for the sudden blurred or lost vision [1].

Three Stabilizing Facts for Your Journey

While the diagnosis is serious, there are several reasons for hope and stability:

  1. Effective Treatments Exist: Unlike a brain stroke, where damage can be permanent and difficult to treat, we have highly effective medications for CRVO. Treatments known as anti-VEGF therapy can significantly reduce swelling and help many patients recover or maintain their vision [4][5].
  2. It Is Not Life-Threatening: While it is called an “eye stroke,” CRVO is typically sight-threatening, not life-threatening [2][6]. It does not mean you are having a brain stroke right now.
  3. Your Good Eye Will Adapt: Many patients worry about losing their independence. Fortunately, if your other eye is healthy, your brain will adapt to rely on it. Your healthy eye will quickly begin to compensate for the vision loss, allowing you to maintain your daily activities.

CRITICAL WARNING: Because patients often associate the word “stroke” with taking Aspirin or other blood thinners, you may be tempted to start taking them. Do NOT start taking over-the-counter Aspirin or blood thinners for your eye unless explicitly instructed by your doctor. Doing so can dangerously worsen the bleeding inside your retina.

Why It Happens: Risk Factors and Prevalence

CRVO is a relatively common vascular condition of the eye, and its prevalence increases as we age [7]. It is often linked to systemic (body-wide) health factors that affect the blood vessels, such as:

  • Hypertension (high blood pressure) [7][2]
  • Hyperlipidemia (high cholesterol) [7][2]
  • Diabetes [8]

In younger patients, other factors like blood clotting disorders or inflammatory conditions may play a role [8][9]. Because CRVO shares risk factors with heart disease, your eye doctor will likely recommend a full physical exam to ensure your blood pressure and cholesterol are well-managed [6][2].

The Emotional Impact

The suddenness of CRVO can take a toll on your quality of life and emotional well-being [10][11]. It is common to experience frustration or sadness as you adjust to vision changes or the prospect of ongoing treatments [10]. Recognizing these feelings is the first step toward managing them. Many patients find that as their vision improves with treatment, their quality of life and sense of well-being also begin to recover [12][11].

Common questions in this guide

What is a central retinal vein occlusion (CRVO)?
CRVO is a blockage in the main vein that carries blood away from your retina. This blockage causes blood and fluid to back up and leak into the eye, often resulting in sudden vision blurriness or loss due to swelling.
Is an eye stroke the same as a brain stroke?
No. While an eye stroke involves a blocked blood vessel similar to a brain stroke, it is typically sight-threatening rather than life-threatening. A CRVO diagnosis does not mean you are actively having a stroke in your brain.
Should I take aspirin for my eye stroke?
You should never start taking over-the-counter aspirin or other blood thinners for an eye stroke unless your doctor explicitly tells you to do so. Unsupervised use of blood thinners can dangerously worsen the bleeding inside your retina.
What causes an eye stroke?
CRVO is often linked to systemic health issues that affect your overall blood vessels. Common risk factors include aging, high blood pressure, high cholesterol, and diabetes.
Will I lose my vision permanently from CRVO?
Not necessarily. Modern medicine has highly effective treatments, such as anti-VEGF therapy, which can significantly reduce the swelling in your eye and help many patients maintain or recover their vision.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my CRVO the 'ischemic' or 'non-ischemic' type, and how does that change my treatment plan?
  2. 2.What is the specific cause of my vision loss right now—is it macular edema (swelling) or a lack of blood flow?
  3. 3.What specific tests should I ask my primary care doctor to run to check my heart and vascular health?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (12)
  1. 1

    Clinical Features of Combined Central Retinal Artery and Vein Occlusion.

    Wang H, Chang Y, Zhang F, et al.

    Journal of ophthalmology 2019; (2019()):7202731 doi:10.1155/2019/7202731.

    PMID: 31687201
  2. 2

    A review of the management of central retinal artery occlusion.

    Madike R, Cugati S, Chen C

    Taiwan journal of ophthalmology 2022; (12(3)):273-281 doi:10.4103/2211-5056.353126.

    PMID: 36248088
  3. 3

    Retinal vein occlusion in COVID-19: A novel entity.

    Sheth JU, Narayanan R, Goyal J, Goyal V

    Indian journal of ophthalmology 2020; (68(10)):2291-2293 doi:10.4103/ijo.IJO_2380_20.

    PMID: 32971697
  4. 4

    Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial.

    Hykin P, Prevost AT, Vasconcelos JC, et al.

    JAMA ophthalmology 2019; (137(11)):1256-1264 doi:10.1001/jamaophthalmol.2019.3305.

    PMID: 31465100
  5. 5

    Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: a systematic review and network meta-analysis.

    Sangroongruangsri S, Ratanapakorn T, Wu O, et al.

    Expert review of clinical pharmacology 2018; (11(9)):903-916 doi:10.1080/17512433.2018.1507735.

    PMID: 30071180
  6. 6

    Risk of Adverse Systemic Events in Retinal Vein Occlusion.

    Albrecht EA, Shukla P, Zhao AH, et al.

    Ophthalmology. Retina 2025; (9(11)):1090-1097 doi:10.1016/j.oret.2025.05.005.

    PMID: 40349983
  7. 7

    Current Understanding of Retinal Vein Thrombosis in Older Adults: A Review of the Literature.

    Smekalkina LV, Safonicheva OG, Kabardina EV, et al.

    Clinical interventions in aging 2025; (20()):2399-2407 doi:10.2147/CIA.S548403.

    PMID: 41368277
  8. 8

    CENTRAL RETINAL VEIN OCCLUSION IN YOUNG INDIVIDUALS: A Comparison of Risk Factors and Clinical Outcomes.

    Rothman AL, Thomas AS, Khan K, Fekrat S

    Retina (Philadelphia, Pa.) 2019; (39(10)):1917-1924 doi:10.1097/IAE.0000000000002278.

    PMID: 30085977
  9. 9

    Risk factors for central retinal vein occlusion in young adults.

    Chen TY, Uppuluri A, Zarbin MA, Bhagat N

    European journal of ophthalmology 2021; (31(5)):2546-2555 doi:10.1177/1120672120960333.

    PMID: 33008264
  10. 10

    Vision-related quality of life in patients with retinal vein occlusion.

    Ramin S, Rostami F, Ahmadieh H, et al.

    International ophthalmology 2024; (44(1)):114 doi:10.1007/s10792-024-02916-1.

    PMID: 38409518
  11. 11

    Vision-related quality of life and subscale items following intravitreal ranibizumab injections for central retinal vein occlusion.

    Okamoto F, Murakami T, Sugiura Y, et al.

    Japanese journal of ophthalmology 2023; (67(1)):59-65 doi:10.1007/s10384-022-00949-6.

    PMID: 36301446
  12. 12

    Relationship between stereopsis and vision-related quality of life following intravitreal ranibizumab injections for central retinal vein occlusion.

    Okamoto F, Tomioka M, Murakami T, et al.

    Scientific reports 2021; (11(1)):20475 doi:10.1038/s41598-021-00094-z.

    PMID: 34650099

This page provides general information about CRVO and eye strokes for educational purposes only. It is not medical advice, and you should never start or stop taking medications—especially blood thinners—without consulting your eye doctor.

Get notified when new evidence is published on Central retinal vein occlusion.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.